Missouri 2022 Regular Session

Missouri Senate Bill SB1147

Introduced
2/11/22  

Caption

Requires the MO HealthNet Division to conduct an annual review of services available for enrollees with sickle cell disease

Impact

With the implementation of SB1147, there will be a shift in the way services for sickle cell disease are approached and evaluated in Missouri. The required annual review not only serves to ensure that enrollees have access to effective therapies but also aims to facilitate a more informed healthcare provider community. By regularly updating treatment protocols and medication lists based on extensive research and community feedback, Missouri could see improvements in the health outcomes of patients affected by sickle cell disease. This potentially positions the state as a leader in addressing health disparities within minority populations.

Summary

Senate Bill 1147 aims to enhance healthcare services for individuals diagnosed with sickle cell disease by mandating the Missouri HealthNet Division to conduct an annual review of medications and treatments available to enrollees suffering from this condition. This review is intended to assess whether the current offerings adequately meet the needs of patients and also evaluate promising treatments that are in late-stage studies, which are highlighted in peer-reviewed medical journals. Additionally, emphasis is placed on provider education regarding the disproportionate impact of sickle cell disease on specific minority communities.

Contention

While the bill presents a structured approach to enhancing care for those with sickle cell disease, it may also pose challenges concerning the evaluation of treatment effectiveness and accessibility. Discussions might arise regarding the potential costs associated with implementing the annual reviews and the subsequent adjustments to healthcare policies that may be necessitated by the findings of these reviews. Moreover, the success of SB1147 heavily relies on the participation and input from various stakeholders, including patients, healthcare providers, and advocacy groups that specialize in sickle cell disease, to create an informed and equitable healthcare landscape.

Companion Bills

No companion bills found.

Previously Filed As

MO SB298

Requires the Louisiana Department of Health to annually review medications, forms of treatment, and services for care of Medicaid enrollees with sickle cell disease. (8/1/22)

MO HB2723

Sickle cell disease; annual review

MO HB820

Sickle cell disease; annual review of medication and treatment, report.

MO HB2084

Sickle cell disease; annual review of medication and treatment, report.

MO HB1666

Appropriation; JSU to conduct review and prepare report about health care services available to Medicaid recipients with sickle cell disease.

MO H1085

Sickle Cell Disease

MO HF5428

Commissioner of human services directed to provide an annual report on treatments for sickle cell disease.

MO SF5492

Sickle cell disease annual report on treatments by the Commissioner of Human services direction provisions

MO HB2927

Relating to sickle cell disease.

MO SB276

AN ACT relating to Medicaid coverage for sickle cell disease.

Similar Bills

No similar bills found.